Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theragenics on the NYSE (TGX) -- Ignore unavailable to you. Want to Upgrade?

To: Ron Kline who wrote (289)	12/25/1999 1:17:00 AM
From: dfloydr	Read Replies (1) \| Respond to of 305

I also posted the following on the Yahoo TGX thread. (Note: That thread has suddenly turned interesting ... the name calling and yammer has been overtaken with some good postings from Therapyu DR and Physicsguru. If you check messages starting at about # 10720 and read through # 10756 you will see some very interesting postings on IBt and some changes in technology they and others are trying.) IBt Press release 12/23/99 Msg: 10757 of 10757 Several interesting points: ie: - they have yet to "obtain the CE Mark required to start the sales in the EU". - they are being distributed in the US. - they state 40,000 patients treated in the US in 1999. - brachy centers in Eu have jumped from 2 in 1998 to 20 in 1999. (Whose seeds are they using? Not IBt's.) Press releases - 23/12/1999 Ibt : first patients treated in the U.S. with the implants of Ibt Seneffe, December 22, 1999. International Brachytherapy sa (IBt on EURO.NM Belgium). The first palladium brachytherapy implants of IBt, InterSource103, have been successfully used in a number of medical centers in the U.S. to treat patients with localized prostate cancer. These first sales have been completed by the American subsidiary of IBt, located in Atlanta, Georgia. On the American market, IBt works in collaboration with BARD, its US distributor and one of the world leaders in medical devices for urology applications. For the European distribution, IBt has already started the procedure to obtain the CE Mark required to start the sales in the EU. IBt anticipates to obtain this authorization in the first part of the year 2000. IBt Inc. has recently opened its web site, www.ibt4seeds.com. The use of the brachytherapy technique for the treatment of localized prostate cancer continues to grow. In the U.S., where brachytherapy has been practiced for over 10 years, more than 40.000 patients with localized prostate cancer have been treated with brachytherapy in 1999. In Europe, new brachytherapy centers appear every year. While only two centers were offering the brachytherapy treatment in early 1998 (in Leeds and Utrecht), there are today more than 20 centers in France, Belgium, Italy, Austria, Greece, Germany, U.K. and in The Netherlands. International Brachytherapy SA, a Belgian start-up company listed on the EURO.NM, has as its mission to develop, manufacture and market on a worldwide basis a complete range of radiotherapeutic implants used in brachytherapy. Brachytherapy is a minimally invasive medical procedure which involves placing implants that contain a small quantity of a radioactive isotope inside the tumor. The precisely positioned implants act to destroy the cancerous cells. The main application of the brachytherapy today is the treatment of localized prostate cancer. Contacts: 064/520 811 Francois Blondel, CFO Serge Lamisse, VP Sales & Marketing